III-话题@MedSci

#III#

818篇内容 | 3481人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1916534, encodeId=33c41916534b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, objectType=article, longId=301850, objectId=439030185039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=439030185039, replyNumber=0, likeNumber=97, createdTime=2023-02-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=439030185039, moduleTitle=ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=439030185039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916497, encodeId=2faa191649e38, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=安可达III期临床研究设计及数据解读, objectType=article, longId=220755, objectId=9535220e55a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9535220e55a8, replyNumber=0, likeNumber=41, createdTime=2022-06-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9535220e55a8, moduleTitle=安可达III期临床研究设计及数据解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9535220e55a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916479, encodeId=4eb819164e938, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标, objectType=article, longId=217965, objectId=b8f721e965b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8f721e965b8, replyNumber=0, likeNumber=102, createdTime=2022-08-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8f721e965b8, moduleTitle=DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8f721e965b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916476, encodeId=b6ba19164e695, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=65, createdTime=2022-07-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916560, encodeId=d013191656035, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, objectType=article, longId=735587, objectId=f431e3558751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f431e3558751, replyNumber=0, likeNumber=86, createdTime=2023-04-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f431e3558751, moduleTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f431e3558751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916481, encodeId=1d381916481e3, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=68, createdTime=2022-05-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916485, encodeId=e48a1916485e9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=90, createdTime=2021-12-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916505, encodeId=3a591916505c6, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, objectType=article, longId=221809, objectId=99492218096b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99492218096b, replyNumber=0, likeNumber=76, createdTime=2022-11-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99492218096b, moduleTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99492218096b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916551, encodeId=af52191655121, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=130, createdTime=2022-07-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916547, encodeId=3421191654e5a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, objectType=article, longId=726861, objectId=e4bce268618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4bce268618c, replyNumber=0, likeNumber=110, createdTime=2022-10-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4bce268618c, moduleTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4bce268618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916473, encodeId=f5a919164e35b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, objectType=article, longId=217668, objectId=1fca21e668fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca21e668fc, replyNumber=0, likeNumber=65, createdTime=2021-12-24, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca21e668fc, moduleTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca21e668fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916541, encodeId=951e191654116, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=73, createdTime=2022-08-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916463, encodeId=8ed619164638e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=JAAD:窄谱紫外线 B 不同增量剂量方案对银屑病III-V 型皮肤治疗效果的比较, objectType=article, longId=216704, objectId=2353216e0426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2353216e0426, replyNumber=0, likeNumber=90, createdTime=2022-04-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2353216e0426, moduleTitle=JAAD:窄谱紫外线 B 不同增量剂量方案对银屑病III-V 型皮肤治疗效果的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2353216e0426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916487, encodeId=91f9191648e47, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=121, createdTime=2022-03-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916504, encodeId=1738191650401, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, objectType=article, longId=221687, objectId=bc7922168e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7922168e72, replyNumber=0, likeNumber=0, createdTime=2022-05-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7922168e72, moduleTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7922168e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916477, encodeId=e9eb19164e77f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, objectType=article, longId=217781, objectId=606a21e7812d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=606a21e7812d, replyNumber=0, likeNumber=64, createdTime=2022-02-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=606a21e7812d, moduleTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=606a21e7812d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916531, encodeId=cc5a1916531cd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, objectType=article, longId=295920, objectId=7e81295920f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e81295920f9, replyNumber=0, likeNumber=79, createdTime=2022-03-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e81295920f9, moduleTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e81295920f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916471, encodeId=092319164e142, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=69, createdTime=2022-02-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916460, encodeId=04191916460c5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Clin Cancer Res：新辅助免疫治疗可提高III-IVA期CSCC-HN患者的病理缓解率, objectType=article, longId=215900, objectId=55d621590076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55d621590076, replyNumber=0, likeNumber=75, createdTime=2022-04-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55d621590076, moduleTitle=Clin Cancer Res：新辅助免疫治疗可提高III-IVA期CSCC-HN患者的病理缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55d621590076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916466, encodeId=4db819164668c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=91, createdTime=2021-10-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

ARD：根据SLE患者I型干扰素基因特征和临床亚组分析Anifrolumab疗效和安全性：两项III期试验汇总数据的事后分析

2023-02-18

juliusluan78 (审核中...)

前往app查看评论内容

#III#

安可达III期临床研究设计及数据解读

2022-06-23

juliusluan78 (审核中...)

前往app查看评论内容

#III#

DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标

2022-08-13

juliusluan78 (审核中...)

前往app查看评论内容

#III#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2022-07-23

juliusluan78 (审核中...)

前往app查看评论内容

#III#

联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募

2023-04-26

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2022-05-07

juliusluan78 (审核中...)

前往app查看评论内容

#III#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2021-12-05

juliusluan78 (审核中...)

前往app查看评论内容

#III#

NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功

2022-11-09

juliusluan78 (审核中...)

前往app查看评论内容

#III#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-07-08

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续

2022-10-25

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床

2021-12-24

juliusluan78 (审核中...)

前往app查看评论内容

#III#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-08-02

juliusluan78 (审核中...)

前往app查看评论内容

#III#

JAAD:窄谱紫外线 B 不同增量剂量方案对银屑病III-V 型皮肤治疗效果的比较

2022-04-23

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-03-10

juliusluan78 (审核中...)

前往app查看评论内容

#III#

NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人

2022-05-25

juliusluan78 (审核中...)

前往app查看评论内容

#III#

JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果

2022-02-01

juliusluan78 (审核中...)

前往app查看评论内容

#III#

帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布

2022-03-26

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2022-02-16

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Clin Cancer Res：新辅助免疫治疗可提高III-IVA期CSCC-HN患者的病理缓解率

2022-04-14

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-10-21

科室
- - 订阅+
  - 更多科室
工具
服务